Derivative Instruments

12 Months Ended

Sep. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

11.    Derivative Instruments

The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. These transactions and balances, including short-term advances between the Company and its subsidiaries, subject the Company’s operations to exposure from exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company mitigates the impact of potential currency transaction gains and losses on short-term intercompany advances through timely settlement of each transaction, generally within 30 days.

The Company also enters into foreign exchange contracts to reduce its exposure to currency fluctuations. Under forward contract arrangements, the Company typically agrees to purchase a fixed amount of U.S. dollars in exchange for a fixed amount of a foreign currency on specified dates with maturities of three months or less. These transactions do not qualify for hedge accounting. Net gains and losses related to these contracts are recorded as a component of "Other (expense) income, net" in the accompanying Consolidated Statements of Operations and are as follows for the fiscal years ended September 30, 2017, 2016 and 2015 (in thousands):

	Fiscal Year Ended September 30,
	2017		2016		2015
Realized (losses) gains on derivatives not designated as hedging instruments	$	(545)	$	1,434	$	628

The Company had the following notional amounts outstanding under foreign currency contracts that do not qualify for hedge accounting at September 30, 2017 and 2016 (in thousands):

September 30, 2017:
	Notional Amount			Notional Amount	Fair Value of		Fair Value of
Buy Currency	of Buy Currency	Sell Currency	Maturity	of Sell Currency	Assets		Liabilities
Japanese Yen	391,500	U.S. Dollar	October 2017	3,473	$	1	$	—
U.S. Dollar	1,074	British Pound	October 2017	800		1		—
Korean Won	3,230,100	U.S. Dollar	October 2017	2,833		—		(8)
U.S. Dollar	6,294	Chinese Yuan	October 2017	41,800		—		(2)
Euro	13,700	U.S. Dollar	October 2017	16,167		—		(62)
British Pound	188	Norwegian Krone	October 2017	2,000		—		—
Singapore Dollar	700	U.S. Dollar	October 2017	515		—		—
U.S. Dollar	226	Israeli Shekel	October 2017	800		—		—
U.S. Dollar	3,600	Swiss Franc	October 2017	3,500		2		—
Euro	19,200	British Pound	October 2017	16,888		—		(74)
					$	4	$	(146)

September 30, 2016:
	Notional Amount			Notional Amount	Fair Value of		Fair Value of
Buy Currency	of Buy Currency	Sell Currency	Maturity	of Sell Currency	Assets		Liabilities
British Pound	190	Swedish Krona	October 2016	2,100	$	1	$	—
Japanese Yen	124,000	U.S. Dollar	October 2016	1,229		—		—
U.S. Dollar	6,107	British Pound	October 2016	4,710		2		—
Euro	13,300	U.S. Dollar	October 2016	14,976		—		(40)
U.S. Dollar	5,815	Chinese Yuan	October 2016	39,000		—		(33)
Korean Won	2,488,000	U.S. Dollar	October 2016	2,255		1		—
Euro	7,482	British Pound	October 2016	6,500		—		(23)
U.S. Dollar	311	Israeli Shekel	October 2016	1,169		1		—
Singapore Dollar	360	U.S. Dollar	October 2016	265		—		—
U.S. Dollar	210	Taiwanese Dollar	October 2016	6,600		—		—
British Pound	171	Norwegian Krone	October 2016	1,800		—		—
					$	5	$	(96)

The fair values of the forward contracts described above are recorded in the Company’s accompanying Consolidated Balance Sheets as "Prepaid expenses and other current assets" and "Accrued expenses and other current liabilities".

Stock Warrants

The stock warrant was less than $0.1 million at September 30, 2016. The BioCision warrant agreement contained net share settlement provisions, which permitted the Company to pay the warrant exercise price using shares issuable under the warrant (“cashless exercise”). The value of the stock warrants fluctuated primarily in relation to the value of BioCision’s underlying securities, either providing an appreciation in value or potentially expiring with no value. Gains and losses on the revaluation of the stock warrant were recognized as a component of "Other (expense) income, net" in the accompanying Consolidated Statements of Operations. During fiscal year 2017, the Company canceled the stock warrant as a portion of the non-cash consideration transferred for the acquisition of Cool Lab, which was measured at fair value on the acquisition date. There were no stock warrants held by the Company at September 30, 2017. Please refer to Note 3, "Acquisitions"; Note 7, "Equity Method and Other Investments" and Note 19 “Fair Value Measurements” for further information on the acquisition of Cool Lab and the stock warrant.